

Supplementary Figure 1. Testing chemotherapy resistant in **(A)** OVCD cells and **(B)** OV90 cells. Cells were cultured for 24 prior to treatment. Cell viability using colony survival assay was performed. % Cell viability was normalized to untreated group. **(C)** Intracellular iron was measured using Phenel Green fluorescence probe. *P-value ≤ 0.05 when compared to untreated. #P-Value≤0.05 when compared to hTER7.



Supplementary Figure 2. Synergistic effect of MnP and Platinum compounds on TOV 21G. Colony survival assay was performed after 24 hr treatment. **(A)** MnP. **(B)** Carboplatin. **(C)** Cisplatin. MnP and drugs were added at the same time.



Supplementary Figure 3. Cell viability correlated with H_2O_2 production after MnP and CBCDA treatment at various time point. **(A)** Extracellular H_2O_2 treatment. **(B)** Cell viability with MTT.



Supplementary Figure 4. Co-treatment of MnP and Carboplatin inhibited mitochondrial respiratory and ATP production in chemo-resistant ovarian cancer. Cells were treated with MnP and/or CBDCA for 6 hr. Live cells were then used for the measurement. Seahorse XF Analyzers was used to measure OCR and ECAR in OV90 **(A,C)** and in OVCD **(B,D)**. Oligo=Oligomycin. FCCP = Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone. AtmA = Antimycin A. 2DG=2-deoxy-d-glucoses.



Supplementary Figure 5. Western blots demonstrated expression of Nrf2 protein after MnP treatment 6 hr.